Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn

Used in the treatment of type 2 diabetes, Zomelis comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors


Representative image

Eris Lifesciences on Tuesday announced acquisition of the trademark Zomelis, for Vildagliptin-based formulations, and its associated trademarks from Novartis AG, Switzerland, for a consideration of $13 million (roughly Rs 93

Also Read

Type 2 diabetes on rise in children and teens: Here's what you must know

Price of key diabetes drug may crash as Novartis risks losing patent

Eris Lifesciences gains 6% as 3% equity changes hands via block deals

Diabetes may cause infertility in men; here are some precautionary measures

Eris Lifesciences hits record low as stock turns ex-date for share buyback

JSPL shares fall after SC defers interim order on Sarda mines case

Cybersecurity firm Lucideus raises $7 mn, doubles valuation to $100 mn

Dialysis centre chain NephroPlus eyes overseas foray; to start with Vietnam

US Court delivers judgement in favour of Eros on 'short and distort' claim

Stalemate on JSPL's Odisha iron ore continues; SC defers hearing

Topics : Novartis

First Published: Dec 3 2019 | 9:00 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to